Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGonzález Gil, Celia
dc.contributor.authorLopes, Thaysa Fedalto
dc.contributor.authorFuster-Tormo, Francisco
dc.contributor.authorGarcía-Chica, Jesús
dc.contributor.authorZhao, Ran
dc.contributor.authorBarba Suñol, Pere
dc.contributor.authorMorgades, Mireia
dc.date.accessioned2023-04-26T09:26:27Z
dc.date.available2023-04-26T09:26:27Z
dc.date.issued2023-04
dc.identifier.citationGonzález-Gil C, Morgades M, Lopes T, Fuster-Tormo F, García-Chica J, Zhao R, et al. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials. Haematologica. 2023 Apr;108(4):969–80.
dc.identifier.issn1528-0020
dc.identifier.urihttps://hdl.handle.net/11351/9421
dc.descriptionGenòmica; leucèmia limfoblàstica aguda de cèl·lules T
dc.description.sponsorshipThis project was supported by the AECC (GC16173697BIGA); ISCIII (PI19/01828 and PI19/01183), co-funded by ERDF/ESF, "A way to make Europe"/"Investing in your future", CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/ “La Caixa”. C Gon-zález-Gil was supported by AGAUR grant (ref: 2020 FI_B2 00210).
dc.language.isoeng
dc.publisherFerrata Storti Foundation
dc.relation.ispartofseriesHaematologica;108(4)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectGenòmica
dc.subjectLeucèmia limfoblàstica - Aspectes genètics
dc.subjectCèl·lules T
dc.subject.meshPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.mesh/genetics
dc.subject.meshGenomics
dc.titleGenomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3324/haematol.2022.281196
dc.subject.decsleucemia-linfoma linfoblástico de células T precursoras
dc.subject.decs/genética
dc.subject.decsgenómica
dc.relation.publishversionhttps://doi.org/10.3324/haematol.2022.281196
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[González-Gil C, Lopes T, Fuster-Tormo F, García-Chica J] Institut d’Investigació contra la Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Morgades M] Departament d’Hematologia Clínica, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Zhao R] Department of Quantitative Health Sciences and Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36325893
dc.identifier.wos000736413906053
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple